Cargando…

Validation of the DECA criteria for allergic conjunctivitis severity and control

BACKGROUND: Allergic conjunctivitis (AC) is usually associated to allergic rhinitis (AR), but the severity and control of ocular symptoms should be assessed independently to improve diagnosis and treatment. The criteria from the Spanish consensus document on allergic conjunctivitis (DECA) aimed to b...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Hernández, M. Cesárea, Navarro, Ana M., Colás, Carlos, del Cuvillo, Alfonso, Sastre, Joaquín, Mullol, Joaquim, Valero, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585176/
https://www.ncbi.nlm.nih.gov/pubmed/33110491
http://dx.doi.org/10.1186/s13601-020-00349-4
_version_ 1783599731317932032
author Sánchez-Hernández, M. Cesárea
Navarro, Ana M.
Colás, Carlos
del Cuvillo, Alfonso
Sastre, Joaquín
Mullol, Joaquim
Valero, Antonio
author_facet Sánchez-Hernández, M. Cesárea
Navarro, Ana M.
Colás, Carlos
del Cuvillo, Alfonso
Sastre, Joaquín
Mullol, Joaquim
Valero, Antonio
author_sort Sánchez-Hernández, M. Cesárea
collection PubMed
description BACKGROUND: Allergic conjunctivitis (AC) is usually associated to allergic rhinitis (AR), but the severity and control of ocular symptoms should be assessed independently to improve diagnosis and treatment. The criteria from the Spanish consensus document on allergic conjunctivitis (DECA) aimed to be used as a patient-reported instrument for AC management. Here we validate these criteria for classifying AC severity and defining its control following COSMIN guidelines recommendations. METHODS: Patients with moderate or severe AR [reflective total nasal symptom score (rTNSS) score ≥ 8] and concomitant AC were recruited from hospitals in Spain. Patients were classified according to the severity of ocular symptoms as mild, moderate, or severe, and classified with respect to control as controlled and non-controlled, using the DECA criteria. To validate these criteria, comparisons with the validated modified allergic rhinitis and its impact on asthma (mARIA), reflective total ocular symptom score (rTOSS), rhinitis control assessment test (RCAT), ESPRINT-15 questionnaires, a conjunctival hyperemia scale and a visual analogue scale (VAS) for ocular symptoms were performed. RESULTS: A total of 128 patients participated in the validation. Mean age was 34.4 ± 12.1 years; 72.7% were women. The DECA criteria showed a good discriminant validity, reflecting a high capacity to differentiate between mild, moderate, and severe patients, and controlled from uncontrolled patients. A strong association between AC and AR was reflected in the comparison between the DECA and the mARIA criteria (p < 0.0001). The DECA criteria for severity and control presented satisfactory properties for longitudinal validity and responsiveness. CONCLUSIONS: Validation of the DECA criteria for severity and control of AC suggested that it can be useful in the evaluation of eye symptoms and follow-up of therapies.
format Online
Article
Text
id pubmed-7585176
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75851762020-10-26 Validation of the DECA criteria for allergic conjunctivitis severity and control Sánchez-Hernández, M. Cesárea Navarro, Ana M. Colás, Carlos del Cuvillo, Alfonso Sastre, Joaquín Mullol, Joaquim Valero, Antonio Clin Transl Allergy Research BACKGROUND: Allergic conjunctivitis (AC) is usually associated to allergic rhinitis (AR), but the severity and control of ocular symptoms should be assessed independently to improve diagnosis and treatment. The criteria from the Spanish consensus document on allergic conjunctivitis (DECA) aimed to be used as a patient-reported instrument for AC management. Here we validate these criteria for classifying AC severity and defining its control following COSMIN guidelines recommendations. METHODS: Patients with moderate or severe AR [reflective total nasal symptom score (rTNSS) score ≥ 8] and concomitant AC were recruited from hospitals in Spain. Patients were classified according to the severity of ocular symptoms as mild, moderate, or severe, and classified with respect to control as controlled and non-controlled, using the DECA criteria. To validate these criteria, comparisons with the validated modified allergic rhinitis and its impact on asthma (mARIA), reflective total ocular symptom score (rTOSS), rhinitis control assessment test (RCAT), ESPRINT-15 questionnaires, a conjunctival hyperemia scale and a visual analogue scale (VAS) for ocular symptoms were performed. RESULTS: A total of 128 patients participated in the validation. Mean age was 34.4 ± 12.1 years; 72.7% were women. The DECA criteria showed a good discriminant validity, reflecting a high capacity to differentiate between mild, moderate, and severe patients, and controlled from uncontrolled patients. A strong association between AC and AR was reflected in the comparison between the DECA and the mARIA criteria (p < 0.0001). The DECA criteria for severity and control presented satisfactory properties for longitudinal validity and responsiveness. CONCLUSIONS: Validation of the DECA criteria for severity and control of AC suggested that it can be useful in the evaluation of eye symptoms and follow-up of therapies. BioMed Central 2020-10-23 /pmc/articles/PMC7585176/ /pubmed/33110491 http://dx.doi.org/10.1186/s13601-020-00349-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sánchez-Hernández, M. Cesárea
Navarro, Ana M.
Colás, Carlos
del Cuvillo, Alfonso
Sastre, Joaquín
Mullol, Joaquim
Valero, Antonio
Validation of the DECA criteria for allergic conjunctivitis severity and control
title Validation of the DECA criteria for allergic conjunctivitis severity and control
title_full Validation of the DECA criteria for allergic conjunctivitis severity and control
title_fullStr Validation of the DECA criteria for allergic conjunctivitis severity and control
title_full_unstemmed Validation of the DECA criteria for allergic conjunctivitis severity and control
title_short Validation of the DECA criteria for allergic conjunctivitis severity and control
title_sort validation of the deca criteria for allergic conjunctivitis severity and control
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585176/
https://www.ncbi.nlm.nih.gov/pubmed/33110491
http://dx.doi.org/10.1186/s13601-020-00349-4
work_keys_str_mv AT sanchezhernandezmcesarea validationofthedecacriteriaforallergicconjunctivitisseverityandcontrol
AT navarroanam validationofthedecacriteriaforallergicconjunctivitisseverityandcontrol
AT colascarlos validationofthedecacriteriaforallergicconjunctivitisseverityandcontrol
AT delcuvilloalfonso validationofthedecacriteriaforallergicconjunctivitisseverityandcontrol
AT sastrejoaquin validationofthedecacriteriaforallergicconjunctivitisseverityandcontrol
AT mulloljoaquim validationofthedecacriteriaforallergicconjunctivitisseverityandcontrol
AT valeroantonio validationofthedecacriteriaforallergicconjunctivitisseverityandcontrol